"Enalapril" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.
| Descriptor ID |
D004656
|
| MeSH Number(s) |
D12.644.456.345.360
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enalapril".
Below are MeSH descriptors whose meaning is more specific than "Enalapril".
This graph shows the total number of publications written about "Enalapril" by people in this website by year, and whether "Enalapril" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 2 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 4 | 0 | 4 |
| 2015 | 2 | 3 | 5 |
| 2016 | 9 | 2 | 11 |
| 2017 | 5 | 2 | 7 |
| 2018 | 4 | 3 | 7 |
| 2019 | 4 | 1 | 5 |
| 2020 | 2 | 0 | 2 |
| 2021 | 3 | 0 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enalapril" by people in Profiles.
-
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial. Circ Heart Fail. 2023 03; 16(3):e010111.
-
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022 06 18; 21(1):110.
-
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022 09; 24(9):1591-1598.
-
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021 09; 23(9):1518-1524.
-
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Circ Heart Fail. 2021 03; 14(3):e008052.
-
Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 02 16; 10(4):e019238.
-
Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail. 2020 11; 22(11):2056-2064.
-
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. JACC Heart Fail. 2020 10; 8(10):859-866.
-
Comparison of echocardiographic measurements to invasive measurements of diastolic function in infants with single ventricle physiology: a report from the Pediatric Heart Network Infant Single Ventricle Trial. Cardiol Young. 2019 Oct; 29(10):1248-1256.
-
Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation. 2019 10 22; 140(17):1369-1379.